Total and free concentrations of Polymyxin B1 may predict Polymyxin B-induced nephrotoxicity: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-07-05 14:15 GMT   |   Update On 2022-07-05 14:15 GMT
Advertisement

China: Monitoring total and free plasma concentrations of Polymyxin B1 may predict Polymyxin B-induced acute kidney injury (AKI) in critically ill patients, a recent study published in Infectious Diseases and Therapy has stated. 

The authors wrote, "in critically ill patients, early therapeutic drug monitoring (TDM) of PMB should be considered. Compared with Cmin (B), Cmax (B) and Cmax (B1) may be helpful for the early prediction of PMB-induced AKI in critically ill patients." 

Advertisement

The correlation between total and free polymyxin B (PMB including PMB1 and PMB2) exposure in vivo and acute kidney injury is not well understood. Considering this, Xin Li, The Clinical Application Research Institute of Antibiotics in Changsha, Changsha, Hunan, China, and colleagues aimed to explore the relationships between plasma exposure of PMB1 and PMB2 and nephrotoxicity and investigate the risk factors for PMB-induced acute kidney injury in critically ill patients. 

For this purpose, the researchers enrolled critically ill patients who used PMB and met the criteria. liquid chromatography-tandem mass spectrometry and equilibrium dialysis was used to analyze the total plasma concentration and plasma binding of PMB1 and PMB2. 

Salient findings of the study include:

  • A total of 89 patients were finally included, and AKI developed in 28.1% of them.
  • The peak concentration of PMB1 (Cmax (B1)) (adjusted odds ratio (AOR) = 1.68), baseline BUN level (AOR = 1.08) and hypertension (AOR = 3.73) were independent risk factors for PMB-induced AKI.
  • The area under the ROC curve of the model was 0.799.
  • When Cmax (B1) was 5.23 μg/ml or more, the probability of AKI was higher than 50%.
  • The ratio of PMB1/PMB2 decreased after PMB preparation entered the body.
  • The protein binding rate in critically ill patients indicated significant individual differences.
  • Free Cmax (B) and free Cmax (B1) levels in the AKI group were significantly higher than those in the non-AKI group.
  • Total and free concentrations of PMB in patients showed a positive correlation.

"In the study, Cmax (B1), baseline BUN levels, and hypertension were identified as independent risk factors for PMB-induced AKI," the authors wrote in their study. PMB1/PMB2 ratio may decrease after PMB preparation entered into the body." "Both the ROC curve and logistic regression model showed that Cmax (B1) was a good predictor for the probability of PMB-induced AKI."

"In critically ill patients, early therapeutic drug monitoring of PMB should be considered," they concluded."Compared with Cmin (B), Cmax (B) and Cmax (B1) may be helpful for the early prediction of PMB-induced AKI in critically ill patients."

Reference:

Deng, Y., Gu, JY., Li, X. et al. Does Monitoring Total and Free Polymyxin B1 Plasma Concentrations Predict Polymyxin B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients. Infect Dis Ther (2022). https://doi.org/10.1007/s40121-022-00655-3

Tags:    
Article Source : Infectious Diseases and Therapy

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News